Kindred Biosciences (KIN) Tops Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 rises as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Kindred Biosciences Announces Third Quarter 2015 Financial Results
November 9, 2015 8:30 AM ESTSAN FRANCISCO, Nov. 9, 2015 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the third quarter ended September 30, 2015 and provided updates on its programs. Â
Development and Corporate Updates
KindredBio continues to advance a diversified portfolio of molecules in a capital efficient manner. Some of the recent highlights include:
SentiKind, or KIND-090, pivotal study. The pivotal field study of SentiKind, a KCNQ potassium channel agonist for post-operative pain in dogs, completed enrollment and the Company plans to report topline results in the coming weeks. The... More